36 results about "Pathogenicity Factors" patented technology

The present invention provides a liver cancer target, and a liver cancer inhibition reagent and a use thereof. According to the present invention, an important pathogenic factor EC-HBV-Fs of liver cancer is determined, the pathogenic factor EC-HBV-Fs can be used as a target to prepare a targeted regulation reagent, and is used for treating liver cancer and blocking a liver cancer process, or the pathogenic factor EC-HBV-Fs can be used as a target to screen for a reagent for targeted regulation. The present invention further provides a nucleic acid inhibitor for targeted regulation. The present invention further provides a target for liver cancer detection. The present invention provides a new way for clinical treatment and detection of liver cancer.

The invention discloses an application of bilobalide in preparation of a product for resisting salmonella typhimurium infection. The bilobalide takes salmonella typhimurium QseB protein as a target, has a good interference effect on an AI-2 quorum sensing signal of salmonella typhimurium and has good pharmacological activity, and particularly, the bilobalide has good pharmacological activity under the condition that the growth of salmonella typhimurium is not inhibited. The motility, biofilm formation and infection pathogenicity of salmonella typhimurium are obviously inhibited. The bilobalide does not influence the growth of salmonella typhimurium, directly acts on pathogenic factors, weakens the pathogenicity of bacteria from the source, does not generate selective pressure on salmonella typhimurium, and does not cause the generation of drug-resistant pathogenic bacteria. Therefore, the bilobalide has a good application prospect in the aspect of development of the salmonella typhimurium infection resisting medicine.

The invention discloses a nano diagnosis and treatment agent capable of monitoring the AS disease course. The diagnosis and treatment agent is prepared from phospholipid, auxiliary lipid, antioxidant nano enzyme, a fluorescent probe compound, a loaded drug and an LDL adsorption functional polymer. According to the AS nano diagnosis and treatment agent, efficient endothelial barrier penetration is achieved by taking LDL, a traditional passive penetration mode depending on the ELVIS effect is broken through, and the plaque penetration efficiency of a fluorescent probe and a treatment medicine is improved; a disease course-related plaque specific imaging system is constructed by taking the migration rate of LDL to the interior and subcutaneous tissues as a dynamic indication, and accurate monitoring of the AS development stage is realized; the antioxidant nano-enzyme with mimic enzyme activity is adopted as a core, active oxygen is removed, oxidation of a key pathogenic factor LDL is inhibited, and the function of slowing down AS progress is achieved. The invention provides a new strategy for realizing the integration of disease course monitoring and diagnosis and treatment of the AS.

The invention belongs to the technical field of biology, and discloses an anti-human CD38 antibody and application thereof. The anti-human CD38 antibody disclosed by the invention can be specifically combined with human CD38 protein, and the combination is stable. The antibody is coupled with an adsorption column to pertinently adsorb B cells in blood, so that the level of pathogenic factors can be quickly reduced, and abnormally activated or pathogenic B cells in circulation and pathogenic factors such as antibodies, cell factors and the like generated by the abnormally activated or pathogenic B cells are quickly reduced, thereby quickly relieving symptoms. The B cells can be cleared relatively specifically, and the influence on other cells is reduced. The traditional Chinese medicine composition has the advantages that time is bought for other treatments, in the acute attack or serious stage of diseases, illness state stabilization is facilitated, favorable conditions are created for subsequent immunoregulation treatment or other targeted treatment, immune imbalance can be improved, the imbalance state of an immune system can be adjusted, and immune homeostasis can be recovered. When necessary, adsorption can be repeatedly carried out to maintain the treatment effect, and the safety is high.

The application provides application of Brassica napus gene BnDTX19 in sclerotinia prevention and control, and is obtained by creating transgenic rapeseed to change the disease resistance of rapeseed material. The application constructs the super-expression and RNAi transgenic rapeseed of BnDTX19, firstly discloses the positive regulation function of the gene on sclerotinia resistance, provides the application of the BnDTX19 gene in obtaining high-sclerotinia-resistant rapeseed material by creating super-expression rapeseed, and the application of the BnDTX19-RNAi rapeseed in obtaining sclerotinia-resistant rapeseed material with weakened sclerotinia resistance. The BnDTX19 gene product provided by the application has the function of transporting the key pathogenic factor oxalic acid of sclerotinia to promote disease resistance, and is a new gene resource suitable for creating and breeding new sclerotinia-resistant rapeseed materials and new varieties.

The invention belongs to the technical field of biological medicine, and particularly discloses a combined tumor marker for noninvasive detection of oral cancer and application of the combined tumor marker. The invention provides application of a reagent for detecting a biomarker in preparation of a product for diagnosing or predicting oral cancer. The biomarker is an RBMX gene and / or an NEK2 gene. The invention finds that the two oral cancer carcinogenic key molecules are significantly highly expressed in oral cancer tissues, and the activity, migration and invasion ability of oral cancer cells can be inhibited by knocking down the expression of RBMX or NEK2, and the cis-platinum drug resistance of the oral cancer cells can be inhibited. According to the invention, RBMX or NEK2 is taken as a tumor marker to detect the oral cancer and has good diagnostic efficacy, and the RBMX and the NEK2 are combined for use, so that the sensitivity and the specificity of diagnosis can be further improved, and the risk of the oral cancer can be more comprehensively judged. The invention also provides application of the two pathogenic factors as inhibition targets in preparation of drugs for oral cancer.

This application applies to the field of genetic engineering technology and provides an mlaC knockout mutant strain, its construction method, and application. The mlaC knockout mutant strain is obtained by knocking out the mlaC gene in highly virulent Klebsiella pneumoniae (hvKP). The examples of this application innovatively discovered that hvKP lacking the mlaC gene exhibited reduced lung growth and lung damage in mice, as well as reduced mortality in mice, indicating that the MlaC protein is a key pathogenic factor in hvKP. Furthermore, secretory protein profiling and Western blot results showed that the MlaC protein can be secreted extracellularly and is present in all Klebsiella pneumoniae (KP) strains. Its sequence is conserved, making it a potential new vaccine target for KP. This application broadens research on the pathogenic mechanism of KP and provides a theoretical basis for its prevention and treatment.

The invention discloses an application of a pathogenic factor of sugarcane smut in regulation and control of pathogenicity of sugarcane smut. The amino acid sequence of the pathogenic protein SsCyp64 is as shown in SEQ ID NO: 2, and the coding amino acid sequence of the pathogenic gene SsCYP64 is as shown in SEQ ID NO: 1. According to the invention, SsCYP64 is knocked out from a sugarcane smut wild type through a PEG-mediated protoplast transformation method, so that a knockout mutant is obtained; and respectively back-supplementing the gene in the knockout mutant to obtain a back-supplemented strain. The SsCYP64 has the advantages that the SsCYP64 knockout mutant has the advantages that the capability of forming double mycelia by sexual coordination is weakened, the sensitivity to H2O2 and the SDS stress tolerance are increased, and the pathogenicity is reduced, so that the SsCYP64 plays an important role in regulating the sexual coordination, the oxidation resistance, the SDS tolerance and the pathogenicity of the sugarcane smut. The invention provides a target gene for developing effective bactericides.

To provide a method for depleting a pathogenic substance by antibody targeted phagocytosis.SOLUTION: The present disclosure relates to a method of depleting or reducing the number of disease-causing agents including host cells, or host cells products, microbes or their products in a human subject upon administration of a molecule that causes targeted phagocytosis and comprises a binding domain that binds a specific phagocytotic receptor, such as Dectin-1, and a binding domain that binds a specific disease-causing agent. In a specific embodiment, a method of the disclosure depletes or reduces the number of disease-causing agents in tissues, blood, or bone marrow by targeted phagocytosis.SELECTED DRAWING: None

The invention provides a therapeutic target for high-risk human papilloma virus infection diseases and application of the therapeutic target. The important pathogenic factor EC-HPV16 / 18-Fs of the human papilloma virus infection disease is determined, and the pathogenic factor EC-HPV16 / 18-Fs can be used as a target to prepare a targeted regulation reagent for treating the human papilloma virus infection disease; or, a reagent for targeted regulation is screened by taking the target as a target. The invention also provides nucleic acid inhibitors for targeted modulation. The invention provides a new target for clinical treatment and detection of human papilloma virus infection diseases.

The invention provides a pathogenic factor for neurodegenerative diseases and application of the pathogenic factor. The pathogenic factor for the neurodegenerative diseases is a PASP-GPR37-IL-6 signal axis. According to the application, the action mechanism of the PASP-GPR37-IL-6 signal axis serving as a neurodegenerative disease (especially Parkinson's disease) pathogenic factor is defined for the first time, the molecular path of neuroinflammation and neurodegenerative diseases regulated and controlled by the oligodendroglia through the signal axis is disclosed, and the research blank of participation of the oligodendroglia in PD pathogenesis in the prior art is filled.

The application provides a tobacco target spot pathogen pathogenic factor RsDN3377, a recombinant plasmid, a bacterial body and a preparation method and application of the bacterial body, and belongs to the technical field of biotechnology.The application screens a pathogenic factor generated by tobacco target spot pathogen infection of a host through an RNA-seq method, and reveals important biological functions of the RsDN3377 protein in pathogenicity of target spot pathogen and host interaction.Based on an agrobacterium infiltration transient expression method, a candidate full-length cDNA is constructed into a recombinant plasmid and a recombinant bacterial body, the recombinant bacterial body is injected into a leaf of a benhamiana tobacco N.benthamiana, and necrosis symptoms of a bacterial infection part are observed to identify a molecular function of the RsDN3377 protein.The results show that the agrobacterium infiltration transient expression protein carrying the gene RsDN3377 can cause the occurrence of cell death symptoms, and provides a new target for development and prevention and control of a tobacco target spot pathogen.

This invention discloses an sgRNA sequence for targeted knockout of the Klebsiella pneumoniae capsular gene cluster and its application. The sgRNA sequence for targeted knockout of the Klebsiella pneumoniae capsular gene cluster includes cps-sgRNA-F as shown in SEQ ID NO.1 and cps-sgRNA-R as shown in SEQ ID NO.2. The sgRNA sequence for targeted knockout of the KL47 capsular gene cluster provided by this invention can specifically target the capsular gene cluster. When constructed into a CRISPR / Cas9 vector system and combined with the λRed homologous recombination system, it can specifically target and knock out the Klebsiella pneumoniae capsular gene cluster, obtaining strains with the capsular gene cluster knocked out. This is beneficial for elucidating important pathogenic factors of Klebsiella pneumoniae and demonstrating the specific function of the KL47 capsular type. The CRISPR / Cas9 system for targeted knockout of the KL47 capsular gene cluster of Klebsiella pneumoniae of this invention can effectively knock out the capsular gene cluster of strains, with high specificity, a simple method, and is easy to promote.

The invention discloses a multi-omics data driven disease target discovery method and system and a computer storage medium, which are combined with causal analysis and multi-omics co-localization to greatly improve the biological credibility and verifiability of candidate genes and reduce noise and false positive results. By integrating genetics, expression regulation and cell state information, pathogenic factors are systematically screened, and the comprehensiveness of target spot discovery is improved; modeling and reasoning are based on a pure calculation process, the experiment cost and time are greatly reduced, and the method is suitable for early exploration and rapid iteration of drug targets. Omics input can be flexibly configured according to different disease types and sample data, and adaptive modeling of various diseases is achieved.

The application discloses an application of a rice smut pathogenicity factor ThSCSP_6 in improving plant disease resistance, and belongs to the technical field of genetic engineering. The amino acid sequence of the rice smut pathogenicity factor ThSCSP_6 is shown as SEQ ID NO:1, and the nucleotide sequence of the coding gene is shown as SEQ ID NO:2. Through cloning and function analysis of the rice smut pathogenicity factor ThSCSP_6, the application helps to reveal the molecular mechanism of specific interaction between a rice smut pathogenicity factor race and a rice variety and evolution, and further effectively controls the occurrence of rice smut.

This invention discloses a pharmaceutical composition and its application in the preparation of drugs for treating CSVD, belonging to the field of biomedical technology. The pharmaceutical composition comprises at least one GLP1R agonist and at least one VEGF-A inhibitor. Through Mendelian randomization studies, this invention discovered and revealed that the protective effect of GLP1R agonists in alleviating WMH is partly mediated by downregulating the specific molecular pathway of vascular endothelial growth factor (VEGF-A), indicating that VEGF-A is not only a pathogenic factor of CSVD but also a key downstream node for the therapeutic effect of GLP1R agonists. Based on the above findings, animal model experiments confirmed that compared to traditional single-target monotherapy, combining GLP1R agonists and VEGF-A inhibitors can synergistically enhance the effects and achieve more comprehensive and precise intervention and treatment of CSVD.

The invention discloses a method for preventing and controlling maize chlorotic mottle virus by using an anti-disease gene ZmCDPK7 and application of the anti-disease gene ZmCDPK7, and belongs to the technical field of plant protection. According to the application, through instantaneous silencing of the ZmCDPK7, an overexpression and knockout line of the ZmCDPK7 is constructed, the resistance reaction of the overexpression and knockout line to maize chlorotic mottle virus infection is analyzed, and it is proved that the ZmCDPK7 positively regulates the immunity of maize to the MCMV. In order to further clarify the molecular mechanism of the ZmCDPK7 for regulating and controlling immunity, interaction between the ZmCDPK7 and a key pathogenic factor P31 of the MCMV is discovered and proved through technologies such as yeast two-hybridization and bimolecular fluorescence complementation. ROS detection proves that the ROS content of the ZmCDPK7 knockout strain is higher than that of a wild type after MCMV infection. In biological and abiotic stress reactions, the resistance of the ZmCDPK7 knockout strain to biological and abiotic stress is proved to be reduced.

The invention belongs to the technical field of gene engineering, and relates to application of fusarium graminearum pathogenic factors in wheat disease resistance breeding. The invention provides a fusarium graminearum pathogenic factor gene combination. The fusarium graminearum pathogenic factor gene combination is composed of an FSE1 gene, an FSE2 gene, an FSE3 gene and an FSE4 gene, the FSE1 gene, the FSE2 gene, the FSE3 gene and the FSE4 gene are silenced at the same time or the expression levels of the FSE1 gene, the FSE2 gene, the FSE3 gene and the FSE4 gene are reduced at the same time, and the pathogenicity of fusarium graminearum can be effectively reduced. The invention constructs a recombinant vector, the recombinant vector targets the fusarium graminearum pathogenic factor gene combination, and after the recombinant vector is introduced into a plant, the expression levels of the FSE1 gene, the FSE2 gene, the FSE3 gene and the FSE4 gene after the plant is infected by fusarium graminearum can be effectively reduced, the disease resistance of the plant to gibberellic disease is improved, and the fusarium graminearum pathogenic factor gene combination is improved. And the main agronomic traits of the plant are not influenced.

The invention provides a chiral nano-drug based on LPS, cfDNA and ROS removal strategies, a preparation method of the chiral nano-drug, a construction method of a delivery system and application of the chiral nano-drug, and the preparation method comprises the following steps: weighing PEI (polyethyleneimine) and L / D-tartaric acid L / D-TA, dissolving the PEI and the L / D-TA in deionized water, and standing to prepare a chiral template PEI-L / D-TA; the polyethyleneimine tartaric acid template catalyzes an organic-inorganic mixed silicon source through a simulated biomineralization reaction to prepare a chiral nano-drug PEI-L / D-TA (at) MON; the PEI-L / D-TA (at) MON is loaded with five therapeutic drugs through an in-situ synthesis method so as to play a synergistic therapeutic effect. The nano-drug with LPS, cfDNA and ROS removal capability is successfully prepared by adopting a one-step method, so that the nano-drug can remove pathogens and a plurality of pathogenic factors such as LPS, cfDNA and ROS through physical adsorption, electrostatic interaction and reduction reaction, the inflammatory cascade reaction is inhibited, the nano-drug shows superiority in the aspect of treatment effect on inflammatory bowel diseases, and the nano-drug has a good application prospect. The application potential in the field of nano medicine is huge, and the material can be used as a drug carrier for loading various clinical drugs to achieve a synergistic treatment effect.

The invention belongs to the technical field of gene engineering, discloses activity identification and application of two valsa mali micro-like RNA (Ribonucleic Acid) coding peptides, and provides two coding peptides Vm-milPEP1-1 and Vm-milPEP1-2 which are generated by a Vm-milR1 primary transcript in the valsa mali Cytospora (= Valsa mali, C.mali), and the amino acid sequences of the two coding peptides are shown as SEQ ID NO: 1 and SEQ ID NO: 2. According to the invention, the coding peptides Vm-milPEP1-1 and Vm-milPEP1-2 are expressed in a wild type strain by utilizing a GUS (glucuronidase) reporter gene and a genetic transformation technology, and the coding expression activity of the coding peptides Vm-milPEP1-1 and Vm-milPEP1-2 is determined through GUS dyeing; the coding peptides Vm-milPEP1-1 and Vm-milPEP1-2 are over-expressed in a wild type strain through a GFP (Green Fluorescent Protein) reporter gene, genetic transformation and other technologies, so that the pathogenicity of valsa ceratosperma of apple trees can be remarkably reduced by regulating the expression quantity of a key pathogenic factor Vm-milR1 of valsa ceratosperma, and the application potential of the coding peptides Vm-milPEP1-1 and Vm-milPEP1-2 in prevention and control of the apple tree canker is defined; the technical support is provided for research and development of a new medicament for preventing and treating apple tree canker.

The application belongs to the technical field of biotechnology, and discloses an anti-human CD19 single-chain antibody and application. The anti-human CD19 single-chain antibody can be specifically combined with human CD19 protein and is stable in combination. By coupling the single-chain antibody with an adsorption column, B cells in blood can be adsorbed in a targeted manner, the level of pathogenic factors can be quickly reduced, and the abnormal activated or pathogenic B cells in circulation and the pathogenic factors such as antibodies, cytokines and the like generated by the B cells can be quickly reduced, so that the symptoms can be quickly relieved. The B cells can be relatively specifically removed, and the influence on other cells can be reduced. Time for other treatments is obtained, and in the acute attack or severe stage of the disease, the disease state can be stabilized, and favorable conditions for subsequent immune regulation treatment or other targeted treatment are created. The immune imbalance can be improved, and the imbalance state of the immune system can be adjusted, and the immune homeostasis can be recovered. The adsorption can be repeatedly performed as necessary to maintain the treatment effect, and the safety is high.

The application belongs to the technical field of biological medicine, and particularly relates to an AXIN2 mutant and application thereof. The application discloses, for the first time, a protein with at least one mutation of p.G288A and p.R714W compared with a wild-type AXIN2 protein, and a nucleic acid encoding the protein, the protein and / or the nucleic acid encoding the protein are pathogenic factors of embryonic development deformity, the embryonic development deformity can be diagnosed by detecting the protein and / or the nucleic acid encoding the protein, and the effect of preventing and / or treating the embryonic development deformity can be achieved by specifically changing the protein and / or the substance encoding the protein.

The invention discloses an alpha / beta hydrolase as a 3-hydroxypalmitate signal molecule degrading enzyme and application of the alpha / beta hydrolase. Alpha / beta hydrolase is obtained through amplification in pseudomonas nitroreducens, and research finds that the alpha / beta hydrolase is a main quenching enzyme with the capability of degrading 3-hydroxypalmitate signal molecules in the pseudomonas nitroreducens and can effectively degrade quorum sensing signals, namely 3-OH PAME, generated by ralstonia solanacearum, so that the quorum sensing signals generated by ralstonia solanacearum can be effectively degraded, and the quorum sensing signals generated by ralstonia solanacearum can be effectively degraded. Normal expression of ralstonia solanacearum pathogenic factors is interfered, and quorum sensing between ralstonia solanacearum is blocked, so that the pathogenicity of ralstonia solanacearum is inhibited, and plant bacterial wilt is effectively prevented and treated. The invention provides a new target for green prevention and treatment of bacterial wilt, and has a wide application prospect in the field of agricultural biocontrol.

The application discloses a VirusTAC platform for targeted degradation of tumor cell membrane protein EGFR and psoriasis extracellular pathogenic factor IL17A and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an immunoglobulin Fc region, the Fc regions corresponding to the first polypeptide chain and the second polypeptide chain are associated by heterodimerization mutation; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain EGFR antibody or IL17A antibody. The platform realizes precise degradation of tumor-related membrane proteins and extracellular proteins by constructing a chimera of a natural ligand and a targeting antibody, and by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4.

The present application provides an enzyme, a strain for producing salidroside, and a production method, and the use of glucosyltransferase U8GT3 and / or opium poppy-derived tyrosine decarboxylase and / or tyrosine decarboxylase mutants in increasing the yield of salidroside synthesized using yeast. The yeast engineered bacteria of the present application can directly synthesize salidroside by metabolizing glucose, methanol, galactose, glycerol, or trehalose. Compared with traditional plant extraction, salidroside is not restricted by climatic and geographical conditions, is environmentally friendly, and the fermentation substrate is common and inexpensive, meeting the strategic needs of national green biomanufacturing. Furthermore, the product contains no potential pathogenic factors, ensuring product quality and safety, making it suitable for use in the fields of medicine, cosmetics, and the like.

This application relates to the field of plant disease biological control technology, and discloses a green control method for blueberry gray mold based on a compound microbial agent. The method involves using methyltrophic Bacillus, Bacillus amyloliquefaciens, and Bacillus buddingus to prepare a highly active surface tension regulating liquid and a hydrophobic modified polysaccharide matrix liquid through induced fermentation. Subsequently, calcium glycinate is added, and a self-emulsifying system is constructed through a high-shear process. This invention solves the problems of conventional microbial agents being difficult to wet and adhere to the high-waxy surface of blueberries and being susceptible to rain erosion. The hydrophobic modified polysaccharide and biosurfactant in the system work synergistically to significantly reduce the contact angle and enhance colonization ability. Simultaneously, the chemical precipitation-biodegradation coupling mechanism constructed by calcium glycinate and Bacillus amyloliquefaciens can specifically remove oxalic acid, the pathogenic factor of gray mold. This composition exhibits good stability and significant control efficacy, making it suitable for the green control of blueberry gray mold.

The present invention relates to a cell-penetrating polypeptide (CPP) comprising an amino acid sequence derived from or consisting of a portion of a pathogenic factor, as well as a complex comprising the CPP, a polynucleotide encoding the CPP or complex, an expression vector encoding the CPP or complex, and a cell comprising the same. The present invention also relates to a method for introducing or delivering a molecule of interest into a cell using the CPP, and the use of the CPP for preventing or treating a disease.

The invention discloses a fusarium pseudograminearum FpCys3 gene, an encoded protein and application of the fusarium pseudograminearum FpCys3 gene, and belongs to the technical field of gene engineering. The protein coded by the FpCys3 gene is mainly located in cytoplasm. After the gene is deleted, the influence on the growth of the fusarium pseudograminearum on a complete culture medium is small, but the pathogenicity of the fusarium pseudograminearum to wheat is almost lost, and an obvious plant defense reaction can be seen at an infection point. The invention also discloses that the glucose solution can promote the FpCys3 to be transferred from cytoplasm to cell nucleus, when the FpCys3 is positioned in the cytoplasm, the level of a pathogenic factor methionine in pathogenic bacteria is positively regulated, and the methionine enters the cell nucleus to play a negative role. The fusarium pseudograminearum can be effectively prevented from infecting wheat by spraying a glucose solution on the surfaces of plants. The results show that FpCys3 is a key regulatory factor for pathopoiesis of fusarium pseudograminearum, and FpCys3 nuclear translocation inducers such as glucose and the like can effectively prevent and control wheat stem rot.

The invention discloses application of an ADAM8 gene and / or ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp and the medicine, and relates to the technical field of biological medicines. According to the application of the ADAM8 gene and / or the ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp, the ADAM8 gene and / or the ADAM8 protein are / is used as a treatment target. The research finds that the gene and protein expression level of ADAM8 are obviously up-regulated in ECRSwNP and NECRSwNP and are mainly distributed in inflammatory cells of epithelium and below the epithelium, which prompts that ADAM8 may be a key pathogenic factor in CRSwNP pathogenesis. By specifically inhibiting the activity of ADAM8, nasal polyp-like lesions can be remarkably relieved, infiltration of eosinophilic granulocytes, neutrophil granulocytes and other inflammatory cells can be reduced, key inflammatory signal pathways can be inhibited, collagen deposition and metal matrix protease expression can be reduced, then inflammatory response and a tissue remodeling process can be effectively relieved, and the application of ADAM8 in treatment of nasal polyp-like diseases can be promoted. The scientificity and clinical application prospect of the ADAM8 as a treatment target are verified.

The application belongs to the technical field of biometric recognition, and relates to a key pathogenic factor screening method based on deep embedding and gene network constraint. The method first acquires a gene expression matrix; a gene interaction network corresponding to the gene expression matrix is constructed to generate a sparse adjacency matrix and a sparse mask matrix; a graph variational autoencoder model with gene network constraint is constructed, the input of the model is the gene expression matrix, the sparse mask matrix M is used in the form of element-level multiplication to limit the weight connection of the encoder, the decoder reconstructs the input gene expression matrix according to the latent structure characteristics, and a multi-task prediction module at the output end predicts the infection stage probability distribution and pathogen load through parallel classification branches and regression branches; the constructed model is trained; feature attribution analysis is performed on the input genes according to the task output of the model, the importance scores of the genes are calculated, and a key gene candidate set is generated. The method significantly improves the biological rationality and stability of the screening result.